The Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, an oral formulation of arsenic trioxide, for the treatment of acute promyelocytic leukemia (APL), an aggressive ...

QTX-2101 is an investigational, oral arsenic trioxide therapy that has not yet been approved by any regulatory authority. Its safety and efficacy are currently under evaluation. This press release ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Arsenic Trioxide Injection in a 10 mg per 10 mL vial presentation. The product is ...

QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid (ATRA) is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- An ...

CHICAGO (Reuters Health) - In adults with newly diagnosed acute promyelocytic leukemia (APL), the addition of arsenic trioxide to standard therapy significantly improves survival, according to a phase ...

CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: Potential predictor of early engraftment. Use of deep whole ...

MDS patients diagnosed according to standard French-American-British criteria received a loading dose of 0.3 mg/kg per day of arsenic trioxide for 5 days followed by a maintenance dose of 0.25 mg/kg ...

A dangerous chemical once used in root canal therapy is back in circulation through illegal channels, sparking fears of lasting damage.